VJHemOnc is committed to improving our service to you

ISA 2020 | Goal of therapy in AL amyloidosis: what predicts the best outcome?

VJHemOnc is committed to improving our service to you

Morie Gertz

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the goal of therapy in immunoglobulin light chain (AL) amyloidosis and what predicts the best outcome, highlighting that free light chain ratio should not be used as a criterion or endpoint of therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter